IRVINE, CA and AMSTERDAM, THE NETHERLANDS, August 29, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, conducted one of its premiere thought leadership events, “Present and Future Trends in Breast Cancer Genomics,” on Saturday, August 25, 2012. The event was held at The Westin Times Square Hotel in New York City and featured over 200 attendees that included leading medical oncologists, pathologists, surgeons and molecular biologists. The conference is one of several events organized by Agendia throughout the year that brings together research scientists and physicians in clinical practice dedicated to the use and development of molecular diagnostics for cancer treatment.
“Events like these demonstrate why it is an exciting time in the field of medical oncology,” said Dr. Stefan Glück, Chairman of Agendia’s Medical Advisory Board. “Breakthrough tools in molecular diagnostics, such as Agendia’s MammaPrint, BluePrint and ColoPrint, play an integral role in helping physicians make clinical decisions about how to most effectively treat their patients. Most importantly, these tools are only the beginning of the precision medicine revolution.”
The event featured an impressive list of speakers and panels on the following topics:
The Science Behind Genomic Based Analysis of Breast Cancer
- René Bernards, PhD
Chief Scientific Officer and Co-Founder, Agendia
Clinical Utility of Molecular Diagnostics
- Ralph V. Boccia, MD, FACP
Clinical Associate Professor of Medicine, Georgetown University
Landmark Clinical Trials
- Stefan Glück, MD, FRCP(C), PhD
Sylvester Professor, Miller School of Medicine, University of Miami
Tumor Round Table Discussion and Case Study Review
- Stephanie Akbari, MD, FACS (Moderator)
Medical Director, Center for Breast Health, Virginia Hospital Center
- Mark A. Gittleman, MD, FACS
Medical Director, Breast Care Specialists and Advanced Breast Care Imaging
- Stefan Glück, MD, PhD
Sylvester Professor, Miller School of Medicine, University of Miami
- James V. Pellicane, MD, FACS
Director, Breast Oncology, Bon Secours Cancer Institute
- Jamie Shutter, MD
Owner, South Beach Medical Consultants
- Hatem Soliman, MD
Assistant Member, Comprehensive Breast Cancer and Experimental Therapeutics, Moffitt Cancer Center and Research Institute
“Seventy five percent of cancer therapies today are ineffective,” said David Macdonald, CEO of Agendia. “This represents 37 billion dollars spent globally on cancer drugs that do not benefit patients. Today’s event further demonstrates Agendia’s commitment to the continued development of clinically reliable diagnostics that provide doctors with decision-making tools needed to improve the effectiveness of cancer therapies for their patients.”
About Agendia:
Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient’s individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.
In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.
For more information, please visit www.agendia.com.
For further information, please contact:
Post+Beam
Melissa Hurley
Tel: +1 646 442 2773
E-mail: hurley@postandbeam.is
